

JC698 U.S. PRO
01/11/02

PATENT
ATTORNEY DOCKET NO.: 044574-5098-US

JC857 U.S. PRO
10/042302
01/11/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner of Patents
BOX PATENT APPLICATION
Washington, D.C. 20231

**TRANSMITTAL FOR A NEWLY EXECUTED ORIGINAL APPLICATION
UNDER 37 C.F.R. §1.53(b)**

This is a request for filing a patent application under 37 C.F.R. §1.53(b) for:

Inventor: Dario C. ALTIERI, Robert M. WEISS, Shannon D. SMITH, Marcia A. WHEELER, and Janet PLESCIA

For: DETECTION OF SURVIVIN IN THE BIOLGICAL FLUIDS OF CANCER PATIENTS

1. This is a new Utility Design Plant patent application.
2. The papers enclosed to obtain a filing date are as follows:

35 Pages of Specification including
0 Title Page
4 Pages of Claims
1 Page of Abstract
4 Sheets of drawings containing 4 Figures
 The enclosed drawings are photographs, and there is also attached a PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)

3. Combined Declaration and Power of Attorney

- Enclosed and is executed by all inventors
 Not Enclosed.

This application is being filed under the provisions of 37 C.F.R. §1.53(f).
Applicant(s) await notification from the Patent and Trademark Office of
the time set for filing the Declaration and paying the filing fees.

4. Language

- English
 Non-English

This application is being filed in accordance with 37 C.F.R. §1.52(d) and §608.01 of the MPEP. Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the verified English translation and the processing fee.

5. Assignment

- An assignment of the invention to _____ and a PTO Form-1595, Recordation Form Cover Sheet, are enclosed.
 An assignment will be filed at a later date.

6. Priority - foreign applications under 35 U.S.C. §119(a)-(d) or §365(b) or PCT international applications under 35 U.S.C. §365(a) designating at least one country other than the U.S.

Priority of the following foreign application is claimed:

Country	Application No.	Filed

Certified copy: is attached. will follow.

7. Priority based on provisional application(s) - 35 U.S.C. §119(e)

Priority of the following provisional application(s) is claimed:

Application No.	Filed
60/260,898	January 12, 2001

A. Relate Back - 35 U.S.C. §119(e)

- Amend the specification by inserting before the first line the sentence:
"This application claims priority of copending provisional application(s)
No. _____ filed on _____."

8. Small entity status

- Applicant(s) hereby assert(s) small entity status under 37 C.F.R. § 1.27.

9. Fee Calculation (37 C.F.R. §1.16)

	Number Filed	Number Extra	at Rate of	Basic Fee Utility \$740.00 Design \$330.00
			BASIC FEE	
Total Claims (37 C.F.R. §1.16(c))				
Independent Claims (37 C.F.R. §1.16(b))				
Multiple dependent claim(s), if any (37 C.F.R. §1.16(d))				
				SUB-TOTAL =
				Reduction by 1/2 for filing by a small entity
				TOTAL FILING FEE =

10. Fee Payment

- Not Enclosed. **NO FEE IS BEING PAID BY CHECK OR DEPOSIT ACCOUNT AT THIS TIME.**

This application is being filed under the provisions of 37 C.F.R. §1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.

- Enclosed.

A check in the amount of \$_____ representing the basic filing fee of \$740.00 and an assignment recording fee of \$40.00 is enclosed

11.

- Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).**

12. Additional papers enclosed:

- Preliminary Amendment
- Information Disclosure Statement
- Form PTO-1449, _____ document included
- Statement Accompanying Sequence Listing
- Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

Please accord this application an application number and filing date.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP



Sally P. Teng
Reg. No. 45,397

Dated: January 11, 2002

Customer No. 09629

MORGAN, LEWIS & BOCKIUS LLP

1800 M Street, N.W.

Washington, D.C. 20036

(202) 467-7000-

PATENT
ATTORNEY DOCKET NO. 44574-5098 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dario C. ALTIERI *et al.*

Application No.: Unassigned

(Based on US Provisional Application 60/260,898)

Filed: January 11, 2002

For: **Detection of Survivin in the Biological Fluids of
Cancer Patients**

)
)
)
)
)
)
)

) Group Art Unit: Unassigned

) Examiner: Unassigned

Box Sequence

Commissioner for Patents
Washington, D.C. 20231

STATEMENT ACCOMPANYING SEQUENCE LISTING

Dear Sir:

The undersigned hereby states upon information and belief that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted herewith.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: January 11, 2002

By: Rachel B. Kapust
Rachel B. Kapust

Customer No. 09629

MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, NW
Washington, D.C. 20036
Tel: 202-467-7000; Fax: 202-467-7258